1
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
Country: UK | Funding: $414M
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
3
Country: USA | Funding: $2.8B
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
4
Country: USA | Funding: $1.5B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
5
Country: USA | Funding: $543M
Lyell Immunopharma is developing a CAR-T cell therapy for colorectal cancer. The therapy targets tumors expressing the guanylate cyclase-C (GCC) protein receptor. GCC is expressed in more than 95% of colorectal cancer cases and in most cases of pancreatic adenocarcinoma. Lyell's genetic reprogramming technologies aim to slow T-cell depletion and generate more potent T-cells with enhanced, sustained anti-tumor activity in the immunosuppressive tumor microenvironment.
Lyell Immunopharma is developing a CAR-T cell therapy for colorectal cancer. The therapy targets tumors expressing the guanylate cyclase-C (GCC) protein receptor. GCC is expressed in more than 95% of colorectal cancer cases and in most cases of pancreatic adenocarcinoma. Lyell's genetic reprogramming technologies aim to slow T-cell depletion and generate more potent T-cells with enhanced, sustained anti-tumor activity in the immunosuppressive tumor microenvironment.
6
Country: USA | Funding: $337M
Alaunos Therapeutics develops immunotherapies for cancer treatment using novel TCR-derived T cells. These cell therapies target neoantigens (neoAgs) arising from genomic mutations in solid tumors. The company has developed proprietary, rapid and cost-effective solutions for the delivery of tumor-specific killer T cells. Alaunos' clinical TCR library targets the most common mutations in the KRAS, TP53 and EGFR genes, which are prevalent in gastrointestinal (colon, bile duct, pancreatic), lung and gynecologic (ovarian and endometrial) cancers across a range of different HLA alleles. Company's propriety non-viral Sleeping Beauty transposon/transposase system is used to introduce the TCR gene into the patient's autologous T cells. Alaunos's current pipeline includes clinical trials against lung, colorectal, pancreatic and ovarian cancers.
Alaunos Therapeutics develops immunotherapies for cancer treatment using novel TCR-derived T cells. These cell therapies target neoantigens (neoAgs) arising from genomic mutations in solid tumors. The company has developed proprietary, rapid and cost-effective solutions for the delivery of tumor-specific killer T cells. Alaunos' clinical TCR library targets the most common mutations in the KRAS, TP53 and EGFR genes, which are prevalent in gastrointestinal (colon, bile duct, pancreatic), lung and gynecologic (ovarian and endometrial) cancers across a range of different HLA alleles. Company's propriety non-viral Sleeping Beauty transposon/transposase system is used to introduce the TCR gene into the patient's autologous T cells. Alaunos's current pipeline includes clinical trials against lung, colorectal, pancreatic and ovarian cancers.
7
Country: USA | Funding: $156M
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
8
Country: USA | Funding: $106M
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
9
Country: Israel | Funding: $72M
Ayala Pharmaceuticals develops a personalized treatment for cancer.
Ayala Pharmaceuticals develops a personalized treatment for cancer.
10
Country: USA | Funding: $40M
Belong is the world’s largest social network for cancer patients and caregivers. The Belong app provides people with cancer and their families a unique and innovative personalized solution to help manage and fight cancer more effectively.
Belong is the world’s largest social network for cancer patients and caregivers. The Belong app provides people with cancer and their families a unique and innovative personalized solution to help manage and fight cancer more effectively.
11
Country: USA | Funding: $11.4M
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
